Navigation Links
Significant Unmet Medical Need for Treatment of Patients with Chronic Pain with Dysphagia (CPD)
Date:4/22/2013

CANTON, Mass., April 22, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the completion of a research study, conducted with an independent market research firm, that identified a significant unmet medical need for improved treatments for patients with chronic pain and dysphagia/odynophagia. In clinical practice, dysphagia is most often defined as difficulty in swallowing and odynophagia is defined as pain upon swallowing. Both conditions may contribute to the inability or difficulty in swallowing solid oral analgesic medications.

Key findings from the research study, which included a review of the medical literature and interviews with physicians who specialize in the treatment of patients with chronic pain, revealed a significant prevalence of dysphagia in this patient population. Chronic pain is a major public health issue in the U.S., affecting approximately 100 million patients. Moreover, approximately 37 million patients suffer from dysphagia. An estimated 11 million people suffer from both chronic pain and dysphagia (Chronic Pain with Dysphagia or "CPD") across a variety of pain subtypes (e.g., chronic back pain, osteoarthritis, and cancer pain). The prevalence of CPD increases with age: 17% of pediatric (0-19 years of age), 24% of adult (20-64 years of age) and 59% of geriatric (>65 years of age) patients.

Treatment options for patients with CPD are limited. Many of these patients cannot swallow a pill and those with more severe dysphagia may require the use of a feeding tube. "Long-acting, extended-release (ER) oral opioids are the treatment of choice for many patients with chronic pain due to less frequent dosing and more consistent plasma concentrations of medication, thereby minimizing end-of-dose breakthrough pain, longer pain control, improved nighttime pain control, and less cl
'/>"/>

SOURCE Collegium Pharmaceutical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Treatment With VP20621 (Non-Toxigenic Clostridium difficile; NTCD) In A Phase 2 Study Resulted In High Rates Of Colonization And Statistically Significant Reductions In Recurrence Of C. difficile Infection
2. Hemodialysis Patient Share for Sanofis Ferrlecit Increased Significantly in the First Quarter of 2013 Compared to the Previous Quarter
3. New Alzheimers Treatment Protocol Produces Significant Results
4. Isis Publishes Data Demonstrating Antisense Targeting of ApoC-III Significantly Reduces ApoC-III and Triglycerides
5. FDA Grants Chimerix Fast Track Designation for CMX001 for the Prevention of Clinically Significant Cytomegalovirus Infection
6. Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
7. New Analysis Shows Age has a Significant Effect on Outcomes in Patients Being Treated for Clostridium difficile Infection (CDI)
8. The Expected Approval of Velcade Will Be a Significant Driver of Growth in the Graft Versus Host Disease Drug Market
9. Rockwell Medical Announces Iron Delivery Drug SFP Meets Primary Endpoint in PRIME Clinical Study Demonstrating Statistically Significant 37% Reduction in ESA Dose
10. IDEV Announces Results from Revascularization with Supera on Real World Patients (RESTORE) Study, Demonstrating Positive Clinical Outcomes in Significantly Diseased Patients with Long Lesions
11. Natural Tree Extract (Larch Arabinogalactan) Shown to Have Statistically Significant Effect in Protecting Immune Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 On ... down 0.52%, the Dow Jones Industrial Average finished the day ... 1,964.68, down 0.41%. The losses were broad based as eight ... S&P 500 Health Care Sector Index ended the day at ... the last one month. Investor-Edge has initiated coverage on the ...
(Date:7/11/2014)... 11, 2014  Veran Medical Technologies, a ... the positive, cost-effective final results for the ... The SPiNPerc endobronchial percutaneous biopsy study results ... to biopsy when a traditional bronchoscopic method ... experience positive financial outcomes when more can ...
(Date:7/10/2014)...  Major advances in radiation therapy and radiosurgery ... in a three-day Oncology Summit taking place in ...  Renowned national and international cancer experts from seven countries ... knowledge on modern technologies making treatment for cancer ... The Summit will address a wide spectrum ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Veran Medical Publishes Lung Cancer Patient Management Study 2Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... April 7, 2011 Cempra Pharmaceuticals Inc. today announced ... will present at two upcoming CHI conferences.  Dr. Fernandes ... Molecule Approaches Conference at 5 p.m. PDT, April ... Diego.  Her presentation is entitled "Macrolides as a New ...
... YORK, April 7, 2011 Reportlinker.com announces that a ... Global Market for Medical Devices, 2nd ... The medical device market is vast -- everything from ... be classified as a type of medical device -- ...
Cached Medicine Technology:Cempra Pharmaceuticals to Present at Two Upcoming Cambridge Healthtech Institute (CHI) Conferences 2Reportlinker Adds Global Market for Medical Devices, 2nd Edition 2Reportlinker Adds Global Market for Medical Devices, 2nd Edition 3Reportlinker Adds Global Market for Medical Devices, 2nd Edition 4Reportlinker Adds Global Market for Medical Devices, 2nd Edition 5
(Date:7/12/2014)... (PRWEB) July 12, 2014 “Critical ... - New and Late-Stage Four-Factor PCCs and Recombinant ... of the critical care market in the US, ... The report provides an estimation of market size ... It covers critical care indications that are being ...
(Date:7/12/2014)... 12, 2014 Utah Valley Entrepreneurial Forum ... with awards being bestowed to companies in revenue, and ... entrepreneur community with recognition for new ideas as well ... incoming revenue. , 25 Under 5 highlights outstanding Utah ... are under 5 years old. Award recipients were recognized ...
(Date:7/12/2014)... July 12, 2014 Praeclarus Press ... Simple as a valuable new resource for women in ... of American women work away from their children. Today’s ... the benefits of breastfeeding, but often feel unsupported when ... their babies. With its evidence-based insights, and written by ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 ... score of 4.1 out of 5. This above-average ... have been underpinning buyer negotiation power over the ... analyst Anna Son, “during the period, surging demand ... costs associated with new product development, have placed ...
(Date:7/12/2014)... 2014 Ladies, it doesn't matter what your ... who are looking for an affordable gown can visit ... dresses) to get their dream items. Recently, the company has ... gowns . Along with that, it is also providing great ... special offer; the deadline of this promotion is July 29, ...
Breaking Medicine News(10 mins):Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Worldwide Brides-to-be: It Is Time To Show Your Beauty By Wearing A Trendy Summer Short Wedding Dress From Discount-Dress.com 2
... Fi-Med,Management, Inc. announced last week the acquisition of ... Utah and southern California., (Logo: http://www.newscom.com/cgi-bin/prnh/20080130/AQW173 ... 2007, comes at the confluence of,two goals: for ... on board for their clients in an IT-savvy ...
... Occupational Safety and Health Administration (OSHA) announced,today in ... for,persons to serve on the National Advisory Committee ... under section 7(a) of the,Occupational Safety and Health ... Labor,and the Secretary of Health and Human Services ...
... IDC on top for the 4th time., ... Ltd.) (TSX: IDL), the global leader in high-quality, ... third consecutive,quarter it received highest ranking in user ... vendors in the January 2008,Intelligence Report by MD ...
... , , WEDNESDAY, Jan. 30 (HealthDay News) -- An operation ... of a major heart artery has a lower ... according to a major new study. , "There have ... of which showed perioperative benefits with EVAR [endovascular aneurysm ...
... Financial Highlights and Potential Milestones include:, - ... Application submission in Q1, - Pixantrone phase ... - Brostallicin phase II interim results SEATTLE, Jan. ... announced today that with the return of CTI,to a ...
... MYL ),today announced that in accordance with its 2.139 ... dividend of $15.53,per share (based on the annual dividend rate ... the time period from the date of,issuance to February 15, ... of record as of February 1, 2008., Mylan Inc. ...
Cached Medicine News:Health News:OSHA Seeking Nominations for National Advisory Committee on Occupational Safety and Health 2Health News:IDC Digital radiography systems Ranked #1 for third consecutive quarter 2Health News:Minimally Invasive Surgery Fixes Aneurysms 2Health News:Minimally Invasive Surgery Fixes Aneurysms 3Health News:Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009 2Health News:Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009 3Health News:Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009 4Health News:Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009 5
... high-power, apochromatically corrected objectives ... the most exacting demands ... are suitable for visual ... 25 mm and feature ...
... transmission rate in the ultraviolet down to ... fluor-3; these objectives have,improved signal to noise ... Numerical Apertures for significantly sharper and brighter ... and a 2mm working distance to allow ...
... Featuring longer working distances with high ... to correct all optical aberrations throughout the ... centre to edges across the entire 25mm ... image flatness and colour reproduction, plus resolving ...
... an extra-high transmission rate, especially in ... to the CFI plan Achromat series, ... observation and photomicrography. Because of ... as multipurpose objectives for brightfield, fluorescence, ...
Medicine Products: